Naturally occurring Clostridium perfringens nontoxic alpha-toxin variant as a potential vaccine candidate against alpha-toxin-associated diseases

Infect Immun. 2001 Nov;69(11):7194-6. doi: 10.1128/IAI.69.11.7194-7196.2001.

Abstract

Clostridium perfringens mutant strain 121A/91 shows neither enzymatic (phospholipase C) nor hemolytic activity. Nevertheless, the cpa gene and the corresponding alpha-toxin variant are detectable. Vaccination with this genetically constructed alpha-toxin variant, rAT121/91, induces antibodies capable of significantly reducing activities induced by wild-type toxin. Thus, rAT121/91 could be a useful vaccine candidate.

MeSH terms

  • Amino Acid Substitution
  • Animals
  • Antibodies, Bacterial / immunology
  • Antibodies, Monoclonal / immunology
  • Antigenic Variation / genetics
  • Antigenic Variation / immunology*
  • Antigens, Bacterial / genetics
  • Antigens, Bacterial / immunology*
  • Antigens, Bacterial / isolation & purification
  • Bacterial Toxins / genetics
  • Bacterial Toxins / immunology*
  • Bacterial Toxins / isolation & purification
  • Bacterial Vaccines / genetics
  • Bacterial Vaccines / immunology*
  • Bacterial Vaccines / isolation & purification
  • Calcium-Binding Proteins*
  • Clostridium Infections / prevention & control
  • Clostridium perfringens / enzymology
  • Clostridium perfringens / genetics
  • Clostridium perfringens / immunology*
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Mutagenesis
  • Type C Phospholipases / genetics
  • Type C Phospholipases / immunology*
  • Type C Phospholipases / isolation & purification
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology*
  • Vaccines, Synthetic / isolation & purification

Substances

  • Antibodies, Bacterial
  • Antibodies, Monoclonal
  • Antigens, Bacterial
  • Bacterial Toxins
  • Bacterial Vaccines
  • Calcium-Binding Proteins
  • Vaccines, Synthetic
  • Type C Phospholipases
  • alpha toxin, Clostridium perfringens